{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:15:18Z","timestamp":1781939718155,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10509-y","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T23:26:24Z","timestamp":1743895584000},"page":"831-841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outpatient worsening heart failure: innovative decongestion strategies and health equity implications"],"prefix":"10.1007","volume":"30","author":[{"given":"Rami","family":"Halaseh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace K.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankeet S.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Svetlichnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirtaz","family":"Adatya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Bensimhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Alexy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Ambrosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"issue":"8","key":"10509_CR1","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","volume":"149","author":"SS Martin","year":"2024","unstructured":"Martin SS, Aday AW, Almarzooq ZI et al (2024) 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation 149(8):e347\u2013e913. https:\/\/doi.org\/10.1161\/CIR.0000000000001209","journal-title":"Circulation"},{"key":"10509_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","volume":"81","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Bauersachs J, Brugts JJ et al (2023) Worsening heart failure: nomenclature, epidemiology, and future directions. J Am Coll Cardiol 81:413\u2013424. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.023","journal-title":"J Am Coll Cardiol"},{"key":"10509_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/RMHP.S130341","volume":"10","author":"M Kilgore","year":"2017","unstructured":"Kilgore M, Patel H, Kielhorn A et al (2017) Economic burden of hospitalizations of Medicare beneficiaries with heart failure. RMHP 10:63\u201370. https:\/\/doi.org\/10.2147\/RMHP.S130341","journal-title":"RMHP"},{"key":"10509_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cardfail.2021.12.017","volume":"28","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Fonarow GC, Opsha Y et al (2022) Economic issues in heart failure in the United States. J Cardiac Fail 28:453\u2013466. https:\/\/doi.org\/10.1016\/j.cardfail.2021.12.017","journal-title":"J Cardiac Fail"},{"key":"10509_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijcard.2020.12.020","volume":"329","author":"CS Kwok","year":"2021","unstructured":"Kwok CS, Abramov D, Parwani P et al (2021) Cost of inpatient heart failure care and 30-day readmissions in the United States. Int J Cardiol 329:115\u2013122. https:\/\/doi.org\/10.1016\/j.ijcard.2020.12.020","journal-title":"Int J Cardiol"},{"key":"10509_CR6","unstructured":"Centers for Medicare and Medicaid Services (2024) Hospital Readmissions Reduction Program (HRRP).  https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/acute-inpatient-pps\/hospital-readmissions-reduction-program-hrrp. Accessed 10 Nov 2024"},{"key":"10509_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/jama.2017.8444","volume":"318","author":"K Dharmarajan","year":"2017","unstructured":"Dharmarajan K, Wang Y, Lin Z et al (2017) Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA 318:270. https:\/\/doi.org\/10.1001\/jama.2017.8444","journal-title":"JAMA"},{"key":"10509_CR8","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.amjmed.2018.06.013","volume":"131","author":"S Angraal","year":"2018","unstructured":"Angraal S, Khera R, Zhou S et al (2018) Trends in 30-day readmission rates for Medicare and non-medicare patients in the era of the affordable care act. Am J Med 131:1324\u20131331.e14. https:\/\/doi.org\/10.1016\/j.amjmed.2018.06.013","journal-title":"Am J Med"},{"key":"10509_CR9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.7326\/M16-0185","volume":"166","author":"JH Wasfy","year":"2017","unstructured":"Wasfy JH, Zigler CM, Choirat C et al (2017) Readmission rates after passage of the hospital readmissions reduction program: a pre\u2013post analysis. Ann Intern Med 166:324\u2013331. https:\/\/doi.org\/10.7326\/M16-0185","journal-title":"Ann Intern Med"},{"key":"10509_CR10","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMsa1513024","volume":"374","author":"RB Zuckerman","year":"2016","unstructured":"Zuckerman RB, Sheingold SH, Orav EJ et al (2016) Readmissions, observation, and the hospital readmissions reduction program. N Engl J Med 374:1543\u20131551. https:\/\/doi.org\/10.1056\/NEJMsa1513024","journal-title":"N Engl J Med"},{"key":"10509_CR11","doi-asserted-by":"publisher","first-page":"e202044","DOI":"10.1001\/jamanetworkopen.2020.2044","volume":"3","author":"GJ Hoffman","year":"2020","unstructured":"Hoffman GJ, Yakusheva O (2020) Association between financial incentives in Medicare\u2019s hospital readmissions reduction program and hospital readmission performance. JAMA Netw Open 3:e202044. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2044","journal-title":"JAMA Netw Open"},{"key":"10509_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2023.09.030","volume":"12","author":"A Lala","year":"2024","unstructured":"Lala A, Hamo CE, Bozkurt B et al (2024) Standardized definitions for evaluation of acute decompensated heart failure therapies. JACC Heart Failure 12:1\u201315. https:\/\/doi.org\/10.1016\/j.jchf.2023.09.030","journal-title":"JACC Heart Failure"},{"key":"10509_CR13","doi-asserted-by":"publisher","first-page":"e006817","DOI":"10.1161\/JAHA.117.006817","volume":"6","author":"M Fudim","year":"2017","unstructured":"Fudim M, Hernandez AF, Felker GM (2017) Role of volume redistribution in the congestion of heart failure. JAHA 6:e006817. https:\/\/doi.org\/10.1161\/JAHA.117.006817","journal-title":"JAHA"},{"key":"10509_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jacc.2022.04.045","volume":"80","author":"AP Ambrosy","year":"2022","unstructured":"Ambrosy AP, Parikh RV, Sung SH et al (2022) Analysis of worsening heart failure events in an integrated health care system. J Am Coll Cardiol 80:111\u2013122. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.045","journal-title":"J Am Coll Cardiol"},{"key":"10509_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ejhf.71","volume":"16","author":"H Skali","year":"2014","unstructured":"Skali H, Dwyer EM, Goldstein R et al (2014) Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J of Heart Fail 16:560\u2013565. https:\/\/doi.org\/10.1002\/ejhf.71","journal-title":"Eur J of Heart Fail"},{"key":"10509_CR16","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","volume":"133","author":"N Okumura","year":"2016","unstructured":"Okumura N, Jhund PS, Gong J et al (2016) Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Circulation 133:2254\u20132262. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.020729","journal-title":"Circulation"},{"key":"10509_CR17","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.120.047480","volume":"142","author":"KF Docherty","year":"2020","unstructured":"Docherty KF, Jhund PS, Anand I et al (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation 142:1623\u20131632. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047480","journal-title":"Circulation"},{"key":"10509_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jchf.2021.01.014","volume":"9","author":"M Vaduganathan","year":"2021","unstructured":"Vaduganathan M, Cunningham JW, Claggett BL et al (2021) Worsening heart failure episodes outside a hospital setting in heart failure with preserved ejection fraction. JACC Heart Failure 9:374\u2013382. https:\/\/doi.org\/10.1016\/j.jchf.2021.01.014","journal-title":"JACC Heart Failure"},{"key":"10509_CR19","doi-asserted-by":"publisher","first-page":"e016010","DOI":"10.1161\/JAHA.119.016010","volume":"9","author":"C Madelaire","year":"2020","unstructured":"Madelaire C, Gustafsson F, Stevenson LW et al (2020) One-year mortality after intensification of outpatient diuretic therapy. JAHA 9:e016010. https:\/\/doi.org\/10.1161\/JAHA.119.016010","journal-title":"JAHA"},{"key":"10509_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamacardio.2017.5250","volume":"3","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Mentz RJ, Felker GM (2018) Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol 3:252. https:\/\/doi.org\/10.1001\/jamacardio.2017.5250","journal-title":"JAMA Cardiol"},{"key":"10509_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jacc.2018.12.034","volume":"73","author":"SJ Greene","year":"2019","unstructured":"Greene SJ, Wilson LE, Abbasi SA et al (2019) Outpatient intravenous diuretic therapy for heart failure in the United States. J Am Coll Cardiol 73:1101\u20131103. https:\/\/doi.org\/10.1016\/j.jacc.2018.12.034","journal-title":"J Am Coll Cardiol"},{"key":"10509_CR22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA et al (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364:797\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa1005419","journal-title":"N Engl J Med"},{"key":"10509_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/jcm13020311","volume":"13","author":"V Bilgeri","year":"2024","unstructured":"Bilgeri V, Spitaler P, Puelacher C et al (2024) Decongestion in acute heart failure\u2014time to rethink and standardize current clinical practice? JCM 13:311. https:\/\/doi.org\/10.3390\/jcm13020311","journal-title":"JCM"},{"key":"10509_CR24","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1093\/eurheartj\/ehab670","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 42:4901\u20134901. https:\/\/doi.org\/10.1093\/eurheartj\/ehab670","journal-title":"Eur Heart J"},{"key":"10509_CR25","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: executive summary. J Am Coll Cardiol 79:1757\u20131780. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011","journal-title":"J Am Coll Cardiol"},{"key":"10509_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jchf.2023.09.029","volume":"12","author":"MW Segar","year":"2024","unstructured":"Segar MW, Khan MS, Patel KV et al (2024) A phenomapping tool and clinical score to identify low diuretic efficiency in acute decompensated heart failure. JACC Heart Failure 12:508\u2013520. https:\/\/doi.org\/10.1016\/j.jchf.2023.09.029","journal-title":"JACC Heart Failure"},{"key":"10509_CR27","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.3390\/jcm12196200","volume":"12","author":"EA Kobe","year":"2023","unstructured":"Kobe EA, McVeigh T, Hameed I, Fudim M (2023) Heart failure remote monitoring: a review and implementation how-to. JCM 12:6200. https:\/\/doi.org\/10.3390\/jcm12196200","journal-title":"JCM"},{"key":"10509_CR28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s10741-024-10426-6","volume":"29","author":"P Wattanachayakul","year":"2024","unstructured":"Wattanachayakul P, Kittipibul V, Salah HM et al (2024) Non-invasive heart failure monitoring: leveraging smart scales and digital biomarkers to improve heart failure outcomes. Heart Fail Rev 29:1145\u20131156. https:\/\/doi.org\/10.1007\/s10741-024-10426-6","journal-title":"Heart Fail Rev"},{"key":"10509_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cardfail.2024.08.033","volume":"31","author":"M Fudim","year":"2025","unstructured":"Fudim M, Feldman DI, Sayed A (2025) Digital health: from remote monitoring to remote care. J Cardiac Fail 31:489\u2013491. https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.033","journal-title":"J Cardiac Fail"},{"key":"10509_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jacbts.2017.10.001","volume":"3","author":"DA Sica","year":"2018","unstructured":"Sica DA, Muntendam P, Myers RL et al (2018) Subcutaneous furosemide in heart failure. JACC: Basic Transl Sci 3:25\u201334. https:\/\/doi.org\/10.1016\/j.jacbts.2017.10.001","journal-title":"JACC: Basic Transl Sci"},{"key":"10509_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/fca-2023-0071","volume":"19","author":"D Bensimhon","year":"2023","unstructured":"Bensimhon D, Weintraub WS, Peacock WF et al (2023) Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study. Future Cardiol 19:385\u2013396. https:\/\/doi.org\/10.2217\/fca-2023-0071","journal-title":"Future Cardiol"},{"key":"10509_CR32","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.jchf.2024.07.015","volume":"12","author":"MA Konstam","year":"2024","unstructured":"Konstam MA, Massaro J, Dhingra R et al (2024) Avoiding treatment in hospital with subcutaneous furosemide for worsening heart failure. JACC Heart Failure 12:1830\u20131841. https:\/\/doi.org\/10.1016\/j.jchf.2024.07.015","journal-title":"JACC Heart Failure"},{"key":"10509_CR33","doi-asserted-by":"publisher","unstructured":"Keshvani N, Rizvi S, Segar MW et al (2024) Diuretic efficiency of a single dose of subcutaneous versus oral furosemide after heart failure hospitalization across diuretic resistance strata: a pilot randomized controlled trial. Eur J Heart Fail 3537. https:\/\/doi.org\/10.1002\/ejhf.3537","DOI":"10.1002\/ejhf.3537"},{"key":"10509_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jacbts.2023.03.002","volume":"8","author":"B Esque","year":"2023","unstructured":"Esque B, Adler ED, Bensimhon D (2023) Novel intranasal loop diuretic. JACC: Basic Transl Sci 8:383\u2013385. https:\/\/doi.org\/10.1016\/j.jacbts.2023.03.002","journal-title":"JACC: Basic Transl Sci"},{"key":"10509_CR35","doi-asserted-by":"publisher","first-page":"072949","DOI":"10.1161\/CIRCULATIONAHA.124.072949","volume":"124","author":"AP Ambrosy","year":"2024","unstructured":"Ambrosy AP, Bensimhon D, Bernstein G et al (2024) Randomized study comparing a novel intranasal formulation of bumetanide to oral and intravenous formulations. Circulation CIRCULATIONAHA 124:072949. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072949","journal-title":"Circulation CIRCULATIONAHA"},{"key":"10509_CR36","doi-asserted-by":"publisher","unstructured":"Tsao CW, Aday AW, Almarzooq ZI et al (2023) Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association. Circulation 147. https:\/\/doi.org\/10.1161\/CIR.0000000000001123","DOI":"10.1161\/CIR.0000000000001123"},{"key":"10509_CR37","doi-asserted-by":"publisher","first-page":"e003553","DOI":"10.1161\/CIRCHEARTFAILURE.116.003553","volume":"10","author":"EA Akwo","year":"2017","unstructured":"Akwo EA, Kabagambe EK, Wang TJ et al (2017) Heart failure incidence and mortality in the Southern Community Cohort Study. Circ Heart Failure 10:e003553. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003553","journal-title":"Circ Heart Failure"},{"key":"10509_CR38","doi-asserted-by":"publisher","first-page":"e003552","DOI":"10.1161\/CIRCOUTCOMES.116.003552","volume":"10","author":"B Ziaeian","year":"2017","unstructured":"Ziaeian B, Kominski GF, Ong MK et al (2017) National differences in trends for heart failure hospitalizations by sex and race\/ethnicity. Circ: Cardiovasc Qual Outcomes 10:e003552. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.116.003552","journal-title":"Circ: Cardiovasc Qual Outcomes"},{"key":"10509_CR39","doi-asserted-by":"publisher","first-page":"e007264","DOI":"10.1161\/CIRCHEARTFAILURE.120.007264","volume":"13","author":"A Nayak","year":"2020","unstructured":"Nayak A, Hicks AJ, Morris AA (2020) Understanding the complexity of heart failure risk and treatment in black patients. Circ Heart Failure 13:e007264. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007264","journal-title":"Circ Heart Failure"},{"key":"10509_CR40","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.amjcard.2019.12.047","volume":"125","author":"S Thakkar","year":"2020","unstructured":"Thakkar S, Majmundar M, Kumar A et al (2020) Comparison of management and outcomes of acute heart failure hospitalization in Medicaid beneficiaries versus privately insured individuals. Am J Cardiol 125:1063\u20131068. https:\/\/doi.org\/10.1016\/j.amjcard.2019.12.047","journal-title":"Am J Cardiol"},{"key":"10509_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11113-016-9416-y","volume":"36","author":"H Sohn","year":"2017","unstructured":"Sohn H (2017) Racial and ethnic disparities in health insurance coverage: dynamics of gaining and losing coverage over the life-course. Popul Res Policy Rev 36:181\u2013201. https:\/\/doi.org\/10.1007\/s11113-016-9416-y","journal-title":"Popul Res Policy Rev"},{"key":"10509_CR42","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM et al (2018) Medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 72:351\u2013366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"key":"10509_CR43","unstructured":"U.S. Government Accountability Office (2020) Rural hospital closures: report to the Ranking Member, Committee on Homeland Security and Governmental Affairs, United States Senate. https:\/\/www.gao.gov\/assets\/gao-21-93.pdf. Accessed 10 Nov 2024"},{"key":"10509_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jchf.2022.08.023","volume":"11","author":"C Witting","year":"2023","unstructured":"Witting C, Zheng J, Tisdale RL et al (2023) Treatment differences in medical therapy for heart failure with reduced ejection fraction between sociodemographic groups. JACC Heart Failure 11:161\u2013172. https:\/\/doi.org\/10.1016\/j.jchf.2022.08.023","journal-title":"JACC Heart Failure"},{"key":"10509_CR45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jacc.2021.11.016","volume":"79","author":"AC Fanaroff","year":"2022","unstructured":"Fanaroff AC, Evans PT, Nathan AS (2022) Rural-urban disparities in cardiovascular outcomes. J Am Coll Cardiol 79:280\u2013282. https:\/\/doi.org\/10.1016\/j.jacc.2021.11.016","journal-title":"J Am Coll Cardiol"},{"key":"10509_CR46","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.121.054516","volume":"144","author":"SU Khan","year":"2021","unstructured":"Khan SU, Javed Z, Lone AN et al (2021) Social vulnerability and premature cardiovascular mortality among US counties, 2014 to 2018. Circulation 144:1272\u20131279. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054516","journal-title":"Circulation"},{"key":"10509_CR47","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jacc.2021.10.045","volume":"79","author":"EC Loccoh","year":"2022","unstructured":"Loccoh EC, Joynt Maddox KE, Wang Y et al (2022) Rural-urban disparities in outcomes of myocardial infarction, heart failure, and stroke in the United States. J Am Coll Cardiol 79:267\u2013279. https:\/\/doi.org\/10.1016\/j.jacc.2021.10.045","journal-title":"J Am Coll Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10509-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10509-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10509-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:04:41Z","timestamp":1753905881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10509-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["10509"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10509-y","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"24 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Bhatt has received research grant support to his institution from National Institutes of Health\/National Heart, Lung, and Blood Institute, National Institutes of Health\/National Institute on Aging, American College of Cardiology Foundation, The Permanente Medical Group, Northern California Community Benefits Programs, Garfield Memorial Fund and the Centers for Disease Control and Prevention and consulting fees from Heart Health Leaders, Sanofi Pasteur, Merck, Amgen, AstraZeneca and Novo Nordisk. Dr. Fudim was supported by the NIH, Alleviant, Gradient, Reprieve, Sardocor, and Doris Duke; he is a consultant and\/or has ownership interest in Abbott, Acorai, Ajax, Alio Health, Alleviant, Artha, Astellas, Audicor, AxonTherapies, Bodyguide, Bodyport, Boston Scientific, Broadview, Cadence, Cardiosense, Cardioflow, Clinical Accelerator, CVRx, Daxor, Edwards LifeSciences, Echosens, EKO, Endotronix, Feldschuh Foundation, Fire1, FutureCardia, Gradient, Hatteras, HemodynamiQ, Impulse Dynamics, ISHI, Lumia Health, Medtronic, NovoNordisk, NucleusRx, Omega, Orchestra, Parasym, Pharmacosmos, Presidio, Procyreon, Proton Intelligence, Puzzle, ReCor, Scirent, SCPharma, Shifamed, Splendo, Summacor, SyMap, Terumo, Vascular Dynamics, Vifor Pharma, Vironix, Viscardia, Zoll. Dr. Greene has received research support from the Duke University Department of Medicine Chair\u2019s Research Award, American Heart Association, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Otsuka, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Lexicon, Lilly, Merck, Novo Nordisk, Otsuka, Roche Diagnostics, Sanofi, scPharmaceuticals, Sumitomo, and Tricog Health; and has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, Novo Nordisk, and Roche Diagnostics. Dr. Adler is chief medical officer and head of research at Lexeo Therapeutics and a scientific advisor and founder for Papillion Therapeutics and Corstasis Therapeutics. Dr. Alexy receives research support from NIH; he is a consultant for Abbott, Edwards Lifesciences LLC, and scPharmaceuticals; his spouse is an employee of Boston Scientific Inc. Dr. Biegus has received honoraria from Bayer, Boehringer Ingelheim, and AstraZeneca for lectures and from Alleviant Medical, Reprieve Cardiovascular, and WhiteSwell for participation in clinical trial advisory boards. Dr. Sauer has received research funding support from Heart Failure Society of America (HFSA), Astra Zeneca, Boehringer Ingelheim, Bayer, CSL Vifor, Pfizer, Rivus Pharmaceuticals, 35Pharma, Novo Nordisk, Edwards Lifesciences, Story Health, and has served as a consultant for Abbott, Boston Scientific, Edwards Lifesciences, Impulse Dynamics, Acorai, General Prognostics, Story Health, Amgen, Bayer. He owns stock in ISHI, Pulsli (both privately held digital health companies). Dr. Pang is, or has been over the last 36 months, a consultant for Incyte Pharmaceuticals, Chugai Pharmaceuticals, Heart Initiative (DSMB), Roche Diagnostics, Eagle Pharmaceuticals, and Kowa Pharmaceuticals; he has received research support by Abbott, Beckman Coulter, Siemens, and the NIH (where he serves as a consultant for a NIH Project); he owns stock in theHeartCourse, and has received funding for other CME work for WebMD. Dr. Collins receives research support from NIH, PCORI, and DOD and is a consultant for Reprieve Cardiovascular, Prenosis, Abbott, Boehringer Ingelheim and Tosoh. Dr. Pandey has received research support from the National Institute on Minority Health and Disparities (R01MD017529), the National Institute of Heart, Lung, and Blood Institute (R21HL169708), American Heart Association, Ultromics, Anumana, and Roche Diagnostics; serves as a consultant for and\/or received honoraria outside of the present study as an advisor\/consultant for Northwestern University, Tricog Health Inc, Lilly USA, Rivus, Cytokinetics, Roche Diagnostics, Sarfez Therapeutics, Edwards Lifesciences, Merck, Bayer, Novo Nordisk, Alleviant, Axon Therapies, Kilele Health, Acorai, Ultromics, Kardigan, Novartis, Idorsia Pharma, and Science37; also served as consultant for Palomarin Inc. with stocks compensation. Dr. Butler is a consultant to Abbott, Adaptyx, American Regent, Amgen, AskBio, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillent, Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultromic, Vera, and Zoll. Dr. Ambrosy has received relevant research support through grants to his institution from the National Heart, Lung, and Blood Institute (K23HL150159 and R01 AG091005), the American Heart Association (2nd Century Early Faculty Independence Award), The Permanente Medical Group, Northern California Community Benefits Programs, Garfield Memorial Fund, Abbott Laboratories, Amarin Pharma, Inc., Bayer, Cordio Medical, Edwards Lifesciences LLC, Esperion Therapeutics, Inc., Merck, and Novartis.\nDr. Andrew P. Ambrosy and Dr. Stephen J. Greene are editorial board members for Heart Failure Reviews. All other authors report no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}